Telitacicept Shows Satisfactory Response in Complex Overlap Syndrome Case
Telitacicept Shows Potential in Rare Overlap Syndrome Case
This is a single case report describing a patient with systemic lupus erythematosus, immune-mediated necrotizing myopathy, Sjögren's syndrom…
A single case report describes a patient with four autoimmune conditions who responded well to a regimen containing telitacicept.
BAFF and APRIL signaling pathways drive pathogenic autoantibody production in IgA nephropathy and lupus nephritis
Biologic Therapies Target Specific Pathways in Kidney Diseases
This systematic review examines the role of BAFF and APRIL signaling pathways in IgA nephropathy, lupus nephritis, and primary membranous ne…
Newer biologic treatments are targeting specific immune pathways to manage conditions like IgA nephropathy and lupus nephritis.
Telitacicept 160 mg plus standard therapy doubles SRI-4 response rate in adults with SLE
Telitacicept shows promise for adults with systemic lupus erythematosus
This meta-analysis of adults with systemic lupus erythematosus (SLE) found that telitacicept 160 mg plus standard therapy increased the SRI-…
A new treatment option, telitacicept, may improve response rates for adults with systemic lupus erythematosus and lupus nephritis.
Telitacicept shows lower incidence of adverse drug reactions in patients with IgA nephropathy
Telitacicept Shows Favorable Safety Profile for IgA Nephropathy
This meta-analysis of observational studies evaluated telitacicept monotherapy and combination therapy for IgA nephropathy. While no statist…
New data suggests telitacicept is a well-tolerated option for IgA nephropathy patients, showing fewer side effects than some other treatment…
Telitacicept reduces proteinuria in adults with IgA nephropathy in Phase 3 trial
New Drug Slashes Kidney Damage Risk in IgA Nephropathy Patients
This is an interim analysis of a Phase 3, multicenter, randomized, placebo-controlled trial in 318 adults with IgA nephropathy and persisten…
A targeted therapy reduced protein in urine by 55 percent more than placebo in people with IgA nephropathy, offering new hope for slowing ki…
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety
New Lupus Treatments Show Stronger Results With Fewer Side Effects
This systematic review and network meta-analysis of 17,121 patients with systemic lupus erythematosus compared biologics and targeted small …
Certain new lupus drugs help more people feel better with fewer flare-ups, especially those struggling with rashes or joint pain that older …
Telitacicept plus standard therapy in SLE patients with antiphospholipid antibodies
New Lupus Drug May Help Patients With Specific Antibodies
This prospective observational cohort study evaluated telitacicept added to standard therapy in 20 SLE patients with antiphospholipid antibo…
A new treatment shows promise for a tough lupus group by targeting specific immune cells.